CN109374899B - ELISA kit for detecting anti-MDA5 antibody and detection method thereof - Google Patents
ELISA kit for detecting anti-MDA5 antibody and detection method thereof Download PDFInfo
- Publication number
- CN109374899B CN109374899B CN201810973433.3A CN201810973433A CN109374899B CN 109374899 B CN109374899 B CN 109374899B CN 201810973433 A CN201810973433 A CN 201810973433A CN 109374899 B CN109374899 B CN 109374899B
- Authority
- CN
- China
- Prior art keywords
- leu
- glu
- asn
- ser
- mda5
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
- G01N2800/202—Dermatitis
Abstract
The invention discloses an ELISA kit for detecting anti-MDA5 antibody. The kit is characterized by comprising purified dominant antigen epitope MDA5 protein. The invention also discloses a detection method of the ELISA kit for detecting the anti-MDA5 antibody. The invention has the beneficial effects that: the MDA5 has difficult full-length expression and high technical requirement, and the price of purchasing the finished MDA5 full-length protein is more expensive. The application expresses the synthetic antigen on the basis of searching the MDA5 dominant epitope, thereby greatly reducing the cost. The kit can be used for detecting the anti-MDA5 antibody, fills the blank of the anti-MDA5 antibody detection method, has the characteristics of large detection flux, exact result, high sensitivity and simple and convenient operation, and is easy to popularize and apply.
Description
Technical Field
The invention belongs to the field of antibody detection, and particularly relates to an ELISA kit for detecting an anti-MDA5 antibody and a detection method thereof.
Background
Dermatomyositis (DM) is a more common life-threatening inflammatory myopathy in the clinic, mainly involving the skin and muscles. Currently considered to fall into the category of autoimmune diseases. The annual incidence rate of dermatomyositis is about 0.5-1/10 ten thousands of people, and the incidence rate is in an ascending trend. In clinical practice we have observed that patients with DM that involve or have skin as the major organ involved, we call "Dermatomyositis inonotus (CADM)" patients with very poor prognosis. According to the existing report and the clinical data of our family, the reason that DM/CADM has poorer prognosis than PM is that the incidence rate of Interstitial Lung Disease (ILD) is extremely high, and the incidence rate is the leading cause of death of DM/CADM patients.
The anti-MDA5 (melanoma differentiation gene 5) antibody is not only a specific antibody of DM/CADM combined ILD, but also a serological marker of DM/CADM patients accompanied with acute lung interstitial lesion, and the antibody level is highly positively correlated with the occurrence and the severity of the lung interstitial lesion and the occurrence of skin ulcer and vasculitis. Dynamic observation of the antibody level in serum is helpful for predicting disease evolution and guiding clinical treatment.
At present, no marketable anti-MDA5 antibody detection kit exists in the domestic market, so that the development of an anti-MDA5 antibody detection kit which can be widely applied, is efficient and sensitive and a corresponding detection method is particularly important for predicting disease evolution and guiding clinical treatment in view of the importance of detecting an anti-MDA5 antibody.
Disclosure of Invention
In order to overcome the defects in the prior art, one of the purposes of the invention is to provide an ELISA kit for detecting anti-MDA5 antibody, wherein the kit contains purified dominant epitope MDA5 protein.
In a preferred embodiment of the present invention, the amino acid sequence group of the purified dominant antigenic epitope MDA5 protein is:
Asn-Ser-Asn-Met-Gly-Ser-Asp-Ser-Gly-Thr-Met-Gly-Ser-Asp-Ser-AspGlu-Glu-Asn-Val-Ala-Ala-Arg-Ala-Ser-Pro-Glu-Pro-Glu-Leu-Gln-LeuLeu-Leu-Asn-Leu-Glu-Asn-Gly-Glu-Asp-Ala-Gly-Val-Gln-Leu-Ser-AspPhe-Ser-Leu-Ile-Ile-Ile-Asp-Glu-Cys-His-His-Thr-Asn-Lys-Glu-AlaVal-Tyr-Asn-Asn-Ile-Met-Arg-His-Tyr-Leu-Met-Gln-Lys-Leu-Lys-AsnLeu-Gly-Leu-Thr-Ala-Ser
in a preferred embodiment of the invention, the kit is provided with an anti-MDA5 antibody detection strip, and the detection strip is a 96-well enzyme label plate coated with dominant epitope MDA5 protein.
In a preferred embodiment of the invention, the kit is further provided with negative control serum, positive control serum, serum diluent, enzyme-labeled secondary antibody, washing solution, substrate developing solution and stop solution.
In a preferred embodiment of the invention, the negative control serum is a CADM patient immunoblotting negative serum for detecting anti-MDA5 antibody, the positive control serum is a CADM patient immunoblotting positive serum for detecting anti-MDA5 antibody, and the enzyme-labeled secondary antibody is horseradish peroxidase-labeled goat anti-human IgG.
The invention also aims to provide a detection method of the ELISA kit for detecting the anti-MDA5 antibody, which comprises the following steps:
(1) coating a 96-well plate with dominant antigen epitope MDA5 protein, and standing overnight at 4 ℃;
(2) washing after coating, removing coating solution, washing with PBST, and repeating for 3-5 times;
(3) adding 5% BSA, incubating at 400 ul/well BSA at room temperature for 2h, washing with PBST, and repeating for 3-5 times;
(4) adding standard (known positive serum) and serum to be detected, 100ul per well, and incubating at normal temperature for 1 h;
(5) dilution of standards and blank control: 1: 40,1: 80,1: 160,1: 320,1: 640,1: 1280,1: 2560, blank: 100ul PBS, test serum 1: 100 mu are added into 100ul of the diluted solution respectively
(6) Washing with PBST for 3-5 times;
(7) adding an enzyme-labeled secondary antibody 1: 2000 (sheep anti-human. HRP), incubation for 30 min at room temperature, washing with PBST, repeating 3-5 times;
(8) adding substrate solution for developing for 15 min;
(9) the reaction was stopped, and read on an 450/630nm microplate reader.
In a preferred embodiment of the invention, in step (1), the dominant epitope MDA5 protein is added at a concentration of 0.5ug/ml to each reaction well, and 100ul is added.
The invention has the following main innovation points:
the MDA5 has difficult full-length expression and high technical requirement, and the price of purchasing the finished MDA5 full-length protein is more expensive. The application expresses the synthetic antigen on the basis of searching the MDA5 dominant epitope, thereby greatly reducing the cost.
The kit can be used for detecting the anti-MDA5 antibody, fills the blank of the anti-MDA5 antibody detection method, has the characteristics of large detection flux, exact result, high sensitivity and simple and convenient operation, and is easy to popularize and apply.
Drawings
FIG. 1 is a diagram of the MDA5 protein structure;
FIG. 2 is a structural diagram of dominant epitope MDA5 protein;
FIG. 3 is a schematic diagram of Western-Blot results of dominant epitope MDA5 protein obtained after protein recombination;
FIG. 4 is a schematic comparison of Anti-MDA5 antibody detection in various groups of humans;
FIG. 5 is a graph showing the comparison of the survival rates of Anti-MDA5 antibody assays.
Detailed Description
The present invention is further illustrated by the following examples, which should not be construed as limiting the invention thereto.
Example 1
1. Because the MDA5 protein has a large structure and a plurality of amino acid sequences, the full-length structure is analyzed by protein dynamics to obtain the dominant antigen structure epitope:
full-length amino acid sequence:
msngystden fryliscfra rvkmyiqvep vldyltflpa evkeqiqrtv atsgnmqave
lllstlekgv whlgwtrefv ealrrtgspl aarymnpelt dlpspsfena hdeylqllnl
lqptlvdkll vrdvldkcme eelltiedrn riaaaenngn esgvrellkr ivqkenwfsa
flnvlrqtgn nelvqeltgs dcsesnaeie nlsqvdgpqv eeqllsttvq pnlekevwgm
ennssessfa dssvvsesdt slaegsvscl deslghnsnm gsdsgtmgsd sdeenvaara
spepelqlrp yqmevaqpal egkni i iclp tgsgktrvav yiakdhldkk kkasepgkvi
vlvnkvllve qlfrkefqpf lkkwyrvigl sgdtqlkisf pevvkscdi i istaqilens
llnlengeda gvqlsdfsli i idechhtnk eavynnimrh ylmqklknnr lkkenkpvip
lpqilgltas pgvggatkqa kaeehilklc anldaftikt vkenldqlkn qiqepckkfa
iadatredpf keklleimtr iqtycqmspm sdfgtqpyeq waiqmekkaa kkgnrkervc
aehlrkynea lqindtirmi daythletfy neekdkkfav ieddsdeggd deycdgdede
ddlkkplkld etdrflmtlf fennkmlkrl aenpeyenek ltklrntime qytrteesar
giiftktrqs ayalsqwite nekfaevgvk ahhligaghs sefkpmtqne qkeviskfrt
gkinlliatt vaeegldike cniviryglv tneiamvqar graradesty vlvahsgsgv
iehetvndfr ekmmykaihc vqnmkpeeya hkilelqmqs imekkmktkr niakhyknnp
slitflcknc svlacsgedi hviekmhhvn mtpefkelyi vrenkalqkk cadyqingei
ickcgqawgt mmvhkgldlp clkirnfvvv fknnstkkqy kkwvelpitf pnldyseccl
fsded
the full-length protein structure is shown in FIG. 1.
After proteome kinetic analysis, the amino acid sequence of the dominant epitope is as follows:
Asn-Ser-Asn-Met-Gly-Ser-Asp-Ser-Gly-Thr-Met-Gly-Ser-Asp-Ser-Asp
Glu-Glu-Asn-Val-Ala-Ala-Arg-Ala-Ser-Pro-Glu-Pro-Glu-Leu-Gln-Leu
Leu-Leu-Asn-Leu-Glu-Asn-Gly-Glu-Asp-Ala-Gly-Val-Gln-Leu-Ser-Asp
Phe-Ser-Leu-Ile-Ile-Ile-Asp-Glu-Cys-His-His-Thr-Asn-Lys-Glu-Ala
Val-Tyr-Asn-Asn-Ile-Met-Arg-His-Tyr-Leu-Met-Gln-Lys-Leu-Lys-Asn
Leu-Gly-Leu-Thr-Ala-Ser
the dominant antigen structure is shown in FIG. 2.
2. After obtaining the dominant antigen epitope amino acid sequence, the dominant antigen epitope protein is obtained by a protein recombination mode, and the method comprises the following steps:
2.1 cloning gene;
2.1.1 obtaining the Gene of interest
The PCR method comprises the following steps: the primers are designed by taking human cDNA containing target genes as a template according to target gene sequences as follows:
F:TCGAATGGGTATTCCACAGACGAGAATTT,R:TCTTGCTGCCACTTCTCTTCTATGAA
the PCR reaction conditions were as follows:
95℃2min；
xm in (2min/kb) at 94 ℃ for 30s,60 ℃ for 30s,68 ℃ for 68 ℃; repeat 35 cycles;
68℃10min；
4℃1min；
and (3) carrying out electrophoresis gel running recovery on the amplification product by using a target fragment recovery kit (QIAGEN QIAqu ickGe l extraction K it) to obtain a purified amplification product.
2.1.2 construction of the cloning plasmid of interest
2.1.2.1 ligation of amplification products
The construction of the connecting body is as follows:
ligation was performed overnight at 16 ℃ to give a ligation product.
2.1.2.2 performing thermal transformation on the ligation products by using competent cells, then inoculating the ligation products to an LB culture plate with corresponding antibiotics for overnight culture, and obtaining a bacterial colony screening plate through transformation; selecting a single colony, transferring the single colony to an LB culture medium containing corresponding antibiotics again for culture, and then taking 2 mu L for PCR identification; after passing the identification, the sample containing the target fragment is inoculated into LB culture medium for overnight rotary culture.
2.1.2.3 the bacterial liquid obtained by culturing is extracted by plasmid according to the standard steps of the kit by using an Axygen miniprep kit, and the obtained plasmid is sequenced to identify whether the plasmid is the target clone plasmid.
2.2 transfection of cells
The obtained target clone plasmid is transfected into HEK293 cells, the transfected cells containing the target clone plasmid are inoculated into corresponding culture media to be cultured for 48-72h, and then the cultured cells are collected.
And 2.3, purifying the protein.
And (3) cracking the collected cells in an ultrasonic crushing mode, then centrifuging at a high speed to collect cracking supernatant, and purifying the cracking supernatant by an affinity purification method to obtain the purified protein.
2.4Western-Blot identification see FIG. 3.
3. Obtaining a large amount of purified dominant antigen protein, and using the dominant antigen protein as an antigen to perform ELISA test, wherein the ELISA test comprises the following steps:
3.1 antigen concentration 0.5ug/ml MDA5ul coated 96-well plate, adding 100ul in each reaction well, 4 degree overnight;
3.2 washing: after coating, removing coating liquid, washing with PBST, and repeating for 3-5 times;
3.3, sealing: 5% BSA, 400 ul/well, incubation at room temperature for 2h, washing, 3.2;
3.4 adding the standard substance and the serum to be detected, 100ul of each hole, and incubating for 1h at normal temperature;
3.5 dilution standard (known positive serum):
diluting a standard product: blank, 1: 40,1: 80,1: 160,1: 320,1: 640,1: 1280,1: 2560;
blank: 100ul PBS, test serum 1: 100 mu is added into 100 mu after being diluted;
3.6 washing, as in 3.2;
3.7 addition of secondary antibody 1: 2000 (goat anti-human. HRP), incubating for 30 min at room temperature, washing, as same as 3.2;
3.8 adding substrate liquid for developing for 15 min;
3.9 stop the reaction, 450/630nm microplate reader reading.
4. Experimental data:
4.1 comparison of Anti-MDA5 antibody detection among various groups of people, it can be seen that Anti-MDA5 antibody expression is significantly increased in ADM-ILD patients, see FIG. 4.
4.2 comparison of survival rates for Anti-MDA5 antibody assays:
by analyzing 85 IIL-ILD patients, the mortality rate of Anti-MDA5 antibody positive patients is obviously higher than that of Anti-MDA5 antibody negative patients, and the result is shown in figure 5.
Sequence listing
<110> Shanghai Feishan Biotechnology Limited
<120> ELISA kit for detecting anti-MDA5 antibody and detection method thereof
<130> 20180815
<160> 3
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1025
<212> PRT
<213> Intelligent (homo sapiens)
<400> 1
Met Ser Asn Gly Tyr Ser Thr Asp Glu Asn Phe Arg Tyr Leu Ile Ser
1 5 10 15
Cys Phe Arg Ala Arg Val Lys Met Tyr Ile Gln Val Glu Pro Val Leu
20 25 30
Asp Tyr Leu Thr Phe Leu Pro Ala Glu Val Lys Glu Gln Ile Gln Arg
35 40 45
Thr Val Ala Thr Ser Gly Asn Met Gln Ala Val Glu Leu Leu Leu Ser
50 55 60
Thr Leu Glu Lys Gly Val Trp His Leu Gly Trp Thr Arg Glu Phe Val
65 70 75 80
Glu Ala Leu Arg Arg Thr Gly Ser Pro Leu Ala Ala Arg Tyr Met Asn
85 90 95
Pro Glu Leu Thr Asp Leu Pro Ser Pro Ser Phe Glu Asn Ala His Asp
100 105 110
Glu Tyr Leu Gln Leu Leu Asn Leu Leu Gln Pro Thr Leu Val Asp Lys
115 120 125
Leu Leu Val Arg Asp Val Leu Asp Lys Cys Met Glu Glu Glu Leu Leu
130 135 140
Thr Ile Glu Asp Arg Asn Arg Ile Ala Ala Ala Glu Asn Asn Gly Asn
145 150 155 160
Glu Ser Gly Val Arg Glu Leu Leu Lys Arg Ile Val Gln Lys Glu Asn
165 170 175
Trp Phe Ser Ala Phe Leu Asn Val Leu Arg Gln Thr Gly Asn Asn Glu
180 185 190
Leu Val Gln Glu Leu Thr Gly Ser Asp Cys Ser Glu Ser Asn Ala Glu
195 200 205
Ile Glu Asn Leu Ser Gln Val Asp Gly Pro Gln Val Glu Glu Gln Leu
210 215 220
Leu Ser Thr Thr Val Gln Pro Asn Leu Glu Lys Glu Val Trp Gly Met
225 230 235 240
Glu Asn Asn Ser Ser Glu Ser Ser Phe Ala Asp Ser Ser Val Val Ser
245 250 255
Glu Ser Asp Thr Ser Leu Ala Glu Gly Ser Val Ser Cys Leu Asp Glu
260 265 270
Ser Leu Gly His Asn Ser Asn Met Gly Ser Asp Ser Gly Thr Met Gly
275 280 285
Ser Asp Ser Asp Glu Glu Asn Val Ala Ala Arg Ala Ser Pro Glu Pro
290 295 300
Glu Leu Gln Leu Arg Pro Tyr Gln Met Glu Val Ala Gln Pro Ala Leu
305 310 315 320
Glu Gly Lys Asn Ile Ile Ile Cys Leu Pro Thr Gly Ser Gly Lys Thr
325 330 335
Arg Val Ala Val Tyr Ile Ala Lys Asp His Leu Asp Lys Lys Lys Lys
340 345 350
Ala Ser Glu Pro Gly Lys Val Ile Val Leu Val Asn Lys Val Leu Leu
355 360 365
Val Glu Gln Leu Phe Arg Lys Glu Phe Gln Pro Phe Leu Lys Lys Trp
370 375 380
Tyr Arg Val Ile Gly Leu Ser Gly Asp Thr Gln Leu Lys Ile Ser Phe
385 390 395 400
Pro Glu Val Val Lys Ser Cys Asp Ile Ile Ile Ser Thr Ala Gln Ile
405 410 415
Leu Glu Asn Ser Leu Leu Asn Leu Glu Asn Gly Glu Asp Ala Gly Val
420 425 430
Gln Leu Ser Asp Phe Ser Leu Ile Ile Ile Asp Glu Cys His His Thr
435 440 445
Asn Lys Glu Ala Val Tyr Asn Asn Ile Met Arg His Tyr Leu Met Gln
450 455 460
Lys Leu Lys Asn Asn Arg Leu Lys Lys Glu Asn Lys Pro Val Ile Pro
465 470 475 480
Leu Pro Gln Ile Leu Gly Leu Thr Ala Ser Pro Gly Val Gly Gly Ala
485 490 495
Thr Lys Gln Ala Lys Ala Glu Glu His Ile Leu Lys Leu Cys Ala Asn
500 505 510
Leu Asp Ala Phe Thr Ile Lys Thr Val Lys Glu Asn Leu Asp Gln Leu
515 520 525
Lys Asn Gln Ile Gln Glu Pro Cys Lys Lys Phe Ala Ile Ala Asp Ala
530 535 540
Thr Arg Glu Asp Pro Phe Lys Glu Lys Leu Leu Glu Ile Met Thr Arg
545 550 555 560
Ile Gln Thr Tyr Cys Gln Met Ser Pro Met Ser Asp Phe Gly Thr Gln
565 570 575
Pro Tyr Glu Gln Trp Ala Ile Gln Met Glu Lys Lys Ala Ala Lys Lys
580 585 590
Gly Asn Arg Lys Glu Arg Val Cys Ala Glu His Leu Arg Lys Tyr Asn
595 600 605
Glu Ala Leu Gln Ile Asn Asp Thr Ile Arg Met Ile Asp Ala Tyr Thr
610 615 620
His Leu Glu Thr Phe Tyr Asn Glu Glu Lys Asp Lys Lys Phe Ala Val
625 630 635 640
Ile Glu Asp Asp Ser Asp Glu Gly Gly Asp Asp Glu Tyr Cys Asp Gly
645 650 655
Asp Glu Asp Glu Asp Asp Leu Lys Lys Pro Leu Lys Leu Asp Glu Thr
660 665 670
Asp Arg Phe Leu Met Thr Leu Phe Phe Glu Asn Asn Lys Met Leu Lys
675 680 685
Arg Leu Ala Glu Asn Pro Glu Tyr Glu Asn Glu Lys Leu Thr Lys Leu
690 695 700
Arg Asn Thr Ile Met Glu Gln Tyr Thr Arg Thr Glu Glu Ser Ala Arg
705 710 715 720
Gly Ile Ile Phe Thr Lys Thr Arg Gln Ser Ala Tyr Ala Leu Ser Gln
725 730 735
Trp Ile Thr Glu Asn Glu Lys Phe Ala Glu Val Gly Val Lys Ala His
740 745 750
His Leu Ile Gly Ala Gly His Ser Ser Glu Phe Lys Pro Met Thr Gln
755 760 765
Asn Glu Gln Lys Glu Val Ile Ser Lys Phe Arg Thr Gly Lys Ile Asn
770 775 780
Leu Leu Ile Ala Thr Thr Val Ala Glu Glu Gly Leu Asp Ile Lys Glu
785 790 795 800
Cys Asn Ile Val Ile Arg Tyr Gly Leu Val Thr Asn Glu Ile Ala Met
805 810 815
Val Gln Ala Arg Gly Arg Ala Arg Ala Asp Glu Ser Thr Tyr Val Leu
820 825 830
Val Ala His Ser Gly Ser Gly Val Ile Glu His Glu Thr Val Asn Asp
835 840 845
Phe Arg Glu Lys Met Met Tyr Lys Ala Ile His Cys Val Gln Asn Met
850 855 860
Lys Pro Glu Glu Tyr Ala His Lys Ile Leu Glu Leu Gln Met Gln Ser
865 870 875 880
Ile Met Glu Lys Lys Met Lys Thr Lys Arg Asn Ile Ala Lys His Tyr
885 890 895
Lys Asn Asn Pro Ser Leu Ile Thr Phe Leu Cys Lys Asn Cys Ser Val
900 905 910
Leu Ala Cys Ser Gly Glu Asp Ile His Val Ile Glu Lys Met His His
915 920 925
Val Asn Met Thr Pro Glu Phe Lys Glu Leu Tyr Ile Val Arg Glu Asn
930 935 940
Lys Ala Leu Gln Lys Lys Cys Ala Asp Tyr Gln Ile Asn Gly Glu Ile
945 950 955 960
Ile Cys Lys Cys Gly Gln Ala Trp Gly Thr Met Met Val His Lys Gly
965 970 975
Leu Asp Leu Pro Cys Leu Lys Ile Arg Asn Phe Val Val Val Phe Lys
980 985 990
Asn Asn Ser Thr Lys Lys Gln Tyr Lys Lys Trp Val Glu Leu Pro Ile
995 1000 1005
Thr Phe Pro Asn Leu Asp Tyr Ser Glu Cys Cys Leu Phe Ser Asp Glu
1010 1015 1020
Asp
1025
<210> 2
<211> 86
<212> PRT
<213> Intelligent (homo sapiens)
<400> 2
Asn Ser Asn Met Gly Ser Asp Ser Gly Thr Met Gly Ser Asp Ser Asp
1 5 10 15
Glu Glu Asn Val Ala Ala Arg Ala Ser Pro Glu Pro Glu Leu Gln Leu
20 25 30
Leu Leu Asn Leu Glu Asn Gly Glu Asp Ala Gly Val Gln Leu Ser Asp
35 40 45
Phe Ser Leu Ile Ile Ile Asp Glu Cys His His Thr Asn Lys Glu Ala
50 55 60
Val Tyr Asn Asn Ile Met Arg His Tyr Leu Met Gln Lys Leu Lys Asn
65 70 75 80
Leu Gly Leu Thr Ala Ser
85
<210> 3
<211> 56
<212> DNA
<213> Artificial sequence (Artificial sequence)
<400> 3
tcgaatgggt attccacaga cgagaatttr tcttgctgcc acttctcttc tatgaa 56
Claims (4)
1. An ELISA kit for detecting anti-MDA5 antibody is characterized in that the kit contains purified dominant antigen epitope MDA5 protein, and the amino acid sequence group of the purified dominant antigen epitope MDA5 protein is as follows:
Asn- Ser- Asn- Met- Gly- Ser-Asp-Ser-Gly-Thr-Met-Gly-Ser-Asp-Ser-Asp
Glu-Glu-Asn-Val-Ala-Ala-Arg-Ala-Ser-Pro-Glu-Pro-Glu-Leu-Gln-Leu
Leu-Leu-Asn-Leu-Glu-Asn-Gly-Glu-Asp-Ala-Gly-Val-Gln-Leu-Ser-Asp
Phe-Ser-Leu-Ile- Ile- Ile-Asp-Glu-Cys-His-His-Thr-Asn-Lys-Glu-Ala
Val-Tyr-Asn-Asn- Ile-Met-Arg-His-Tyr-Leu-Met-Gln-Lys-Leu-Lys-Asn
Leu-Gly-Leu-Thr-Ala-Ser。
2. the ELISA kit of claim 1 for detecting anti-MDA5 antibody, wherein the kit is provided with an anti-MDA5 antibody detection strip, and the detection strip is a 96-well ELISA plate coated with dominant antigen epitope MDA5 protein.
3. The ELISA kit for detecting anti-MDA5 antibody of claim 1, wherein the kit further comprises negative control serum, positive control serum, serum diluent, enzyme-labeled secondary antibody, washing solution, substrate developing solution, and stop solution.
4. The ELISA kit of claim 3 for detecting anti-MDA5 antibody, wherein the negative control serum is CADM patient immunoblotting anti-MDA5 antibody negative serum, the positive control serum is CADM patient immunoblotting anti-MDA5 antibody positive serum, and the enzyme-labeled secondary antibody is horseradish peroxidase-labeled goat anti-human IgG.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810973433.3A CN109374899B (en) | 2018-08-24 | 2018-08-24 | ELISA kit for detecting anti-MDA5 antibody and detection method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810973433.3A CN109374899B (en) | 2018-08-24 | 2018-08-24 | ELISA kit for detecting anti-MDA5 antibody and detection method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109374899A CN109374899A (en) | 2019-02-22 |
| CN109374899B true CN109374899B (en) | 2021-07-30 |
Family
ID=65404533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810973433.3A Active CN109374899B (en) | 2018-08-24 | 2018-08-24 | ELISA kit for detecting anti-MDA5 antibody and detection method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109374899B (en) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101016336A (en) * | 2007-03-07 | 2007-08-15 | 中国人民解放军军事医学科学院微生物流行病研究所 | A-type kreotoxin B cell antigen epitope peptide and use thereof |
| CN101289496B (en) * | 2008-05-30 | 2011-06-29 | 中国医学科学院医学生物学研究所 | Epitope screening method capable of exciting anti-mycobacterium tuberculosis protective immunological reaction of body and uses |
| CN102138072B (en) * | 2008-09-01 | 2015-07-22 | 学校法人庆应义塾 | Diagnosis method and diagnosis kit for dermatomyositis |
| CN102153625A (en) * | 2010-06-22 | 2011-08-17 | 浙江天科高新技术发展有限公司 | Dominant epitopes for identification of anti-Titin antibodies and application thereof |
| CN103336133A (en) * | 2013-07-09 | 2013-10-02 | 上海交通大学医学院附属瑞金医院 | Kit used for detection of anti-MDA5 antibody and detecting method thereof |
| CN105974124A (en) * | 2016-05-19 | 2016-09-28 | 中南大学 | Non-radioactive label immunoprecipitation method for detecting specific self-antibody MDA5 of inflammatory myopathy |
-
2018
- 2018-08-24 CN CN201810973433.3A patent/CN109374899B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN109374899A (en) | 2019-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9068988B2 (en) | Compositions and methods of detecting TIABs | |
| CN111499746B (en) | High-affinity rabbit monoclonal antibody for human interleukin-2 and application thereof | |
| CN101235090B (en) | Specificity fusion protein applied to tuberculosis rapid diagnosis and its construction method | |
| CN101419237B (en) | ELISA fleck diagnosis kit for tubercle bacillus infect and method for preparing specific antigen | |
| WO2023186189A2 (en) | Hybridoma cell strain secreting acta monoclonal antibody, and use thereof | |
| CN111333727B (en) | Binding protein containing NT-proBNP antigen binding structural domain | |
| CN114276445B (en) | Rotavirus recombinant protein specific antibody, plasmid vector and method | |
| CN114349855B (en) | Novel coronavirus Delta mutant strain specific antibody and application thereof | |
| CN108196061B (en) | Double-sandwich ELISA kit for detecting human PGRN based on monoclonal antibody | |
| CN111596070B (en) | Application of portunus trituberculatus tropomyosin allergy detection reagent | |
| CN109374899B (en) | ELISA kit for detecting anti-MDA5 antibody and detection method thereof | |
| CN112300252A (en) | Prediction of 2019-nCoV coronavirus nucleocapsid protein epitope polypeptide and application of polypeptide in detection | |
| KR20180104038A (en) | Methods and kits for the diagnosis of active tuberculosis | |
| KR20210118808A (en) | Anti-pandemic-specific antimalarial lactate dehydrogenase antibody | |
| CN113121678A (en) | Recombinant antibody for resisting HIV-1P24 | |
| CN112679607B (en) | Preparation method of troponin I E13 single-chain antibody | |
| CN115073613A (en) | Fusion protein GLuc-p30 and preparation method and application thereof | |
| CN113004405B (en) | Isolated binding protein comprising NT-proBNP antigen binding domain | |
| CN107664694A (en) | A kind of ELISA kit based on E2 Protein Detection pig atypia pestivirus antibody | |
| CN104560911B (en) | A kind of fusion antigen protein matter | |
| CN109187987B (en) | Application of MS4A3 protein as marker in diagnosis of active tuberculosis | |
| CN114705853A (en) | ELISA kit for detecting NXP2 antibody, detection method and application thereof | |
| CN115047191A (en) | ELISA kit for detecting anti-OJ antibody, detection method and application thereof | |
| CN104558135B (en) | A kind of antigen protein with 65 antibody specific bond of glutamte dehydrogenase | |
| CN116987194B (en) | Anti-idiotype nano antibody of mimic epitope peptide of human ST2 antigen and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wang Kaiwen Inventor after: Zhao Jiangfeng Inventor after: Wang Zhongwei Inventor before: Wang Zhongwei |
|
| CB03 | Change of inventor or designer information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230906 Address after: 201899 No. 1 Chengbei Road, Jiading District, Shanghai Patentee after: Shanghai Jiading District Central Hospital (Jiading District Central Hospital Affiliated to Shanghai Health Medical College and Jiading Branch of Renji Hospital Affiliated to Medical College of Shanghai Jiaotong University) Address before: 201200 room 237, zone B, floor 2, building 2, No. 58, Xiangke Road, pilot Free Trade Zone, Pudong New Area, Shanghai Patentee before: SHANGHAI FEISHENG BIO-TECH Co.,Ltd. |
|
| TR01 | Transfer of patent right |